Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$29.02 ▼ -0.02
(-0.07%)
MKT CAP: $516.9M • VOL: 159.3K
52W L $11 52W H $38
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$24
MEDIAN
$33
MEAN
$33
HIGH
$39
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SRZN TAPE
SRZN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $35.11 | $33.37 | 2025-02-14 | $26.41 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $36.57 | $34.24 | 2025-02-06 | $27.28 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $33.08 | $31.92 | 2025-01-29 | $27.86 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $29.60 | — | 2025-01-17 | $28.44 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $25.54 | $27.57 | 2025-01-09 | $25.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $34.53 | $30.18 | 2024-12-18 | $25.25 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $28.15 | $29.31 | 2024-12-04 | $26.99 | -4.3% | 48% | C |